Expert report

A venture-backed biotech company, developing a clinical stage asset for the treatment of early stage cancer, was populating a dataroom and preparing for negotiations with a major pharmaceutical...
Learn More

Cancer immunotherapy consulting

Alacrita Consulting's founders worked together for over 10 years at Onyvax, a London-based cancer immunotherapy company backed by SR One. We have conducted a number of consulting projects in the...
Learn More

Strategy for biomarker identification technology

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of...
Learn More

Novel Antibody Screening Technology

Technology Consulting: Novel Antibody Screening Technology Alacrita's antibody consultants were asked to help assess the market potential and develop a commercialization strategy for a novel antibody...
Learn More

Monoclonal antibodies to treat bacterial infections

Biologics Consulting: Antibodies to Treat Bacterial Infections An established US biotech company with $bn sales was looking for a team of expert antibody consultants to help them understand the...
Learn More

Radiopharmaceuticals

Alacrita's radiopharmaceuticals consultant has had a distinguished career in the nuclear medicine industry. For a recent radiopharmaceuticals strategy project for a major public/private investor in a...
Learn More

Intellectual Property Analysis & Strategy

Due diligence For a financial investor, Alacrita conducted an IP assessment on a late stage cell therapy  investment opportunity. The assessment revealed that the US and EPO patents relied on just...
Learn More

Managing preclinical programs into Phase I/II clinical trials

Challenge: A leading cancer research charity needed project management and drug development expertise to shepherd two preclinical programs into Phase I/II clinical trials. Alacrita was engaged to...
Learn More

Antibodies

Target Assessment and intellectual property For a mid-cap pharmaceutical company seeking to establish a biologics pipeline through partnership with a mAb development boutique, Alacrita assessed the...
Learn More

Regulatory Affairs: BLA submission support

Background Alacrita`s client was nearing the completion of a pivotal Phase III with a novel antibody-based therapeutic. The product was designed to delay recurrence in cancer patients with minimum...
Learn More
Content not found